NEWARK, CA -- (Marketwired) -- 02/25/14 -- CymaBay Therapeutics, Inc. (OTCQB: CYMA) today announced that Harold Van Wart, President and Chief Executive Officer, will present an overview of the company at investment conferences hosted by Cowen and Company and ROTH Capital Partners.
Cowen and Company 34th Annual Health Care Conference
The Boston Marriott Copley Place, Boston, MA
Monday, March 3
4:50 - 5:20 p.m. EST
A live and archived webcast of CymaBay's presentation at the Cowen conference will be accessible on CymaBay's website at http://www.cymabay.com
ROTH 26th Annual Conference
The Ritz Carlton, Laguna Niguel, CA
Monday, March 10
3:00 - 3:30 p.m. PST
CymaBay Therapeutics is a clinical-stage biopharmaceutical company developing breakthrough therapies addressing unmet medical needs. Arhalofenate, the company's lead product candidate, possesses two therapeutic actions in a single drug. In gout patients, arhalofenate is intended to prevent painful attacks in joints while at the same time promoting excretion of uric acid by the kidney, thereby removing the root cause of this debilitating disease.
For additional information about CymaBay visit www.cymabay.com.
Source: CymaBay Therapeutics